A 24-year-old woman comes to the clinic for a routine follow-up evaluation. Three months a… — USMLE Step 2 CK

A 24-year-old woman comes to the clinic for a routine follow-up evaluation. Three months ago, she was prescribed a combined oral contraceptive pill for primary dysmenorrhea and mild facial acne. She reports that her menstrual cramps have significantly improved and she is satisfied with the medication. She has no other medical conditions and takes no other medications. She denies any fatigue, weight changes, palpitations, heat or cold intolerance, or changes in bowel habits.

Her blood pressure is 112/72 mm Hg, and pulse is 70/min. Physical examination reveals a normal-sized, non-tender thyroid gland with no palpable nodules. Her skin is warm and dry, and there is mild residual acne on her chin.

Laboratory studies are obtained as part of a routine health screening:
Thyroid-stimulating hormone (TSH): $1.7 \text{ \mu U/mL}$ (Normal: $0.4-4.0 \text{ \mu U/mL}$ )
Free thyroxine (Free T4): $1.3 \text{ ng/dL}$ (Normal: $0.8-1.8 \text{ ng/dL}$ )
Total thyroxine (Total T4): $14.2 \text{ \mu g/dL}$ (Normal: $4.5-10.9 \text{ \mu g/dL}$ )

Which of the following is the most appropriate next step in the management of this patient?

A
Order a radioactive iodine uptake scan
B
Measure serum testosterone and dehydroepiandrosterone sulfate levels
Reassurance and continuation of current regimenAnswer
D
Measure serum free triiodothyronine (Free T3) levels
E
Initiate low-dose methimazole therapy

Answer

The correct management is reassurance and continuation of the current regimen, as the laboratory findings represent a normal physiological variant caused by medication.

The correct approach is reassurance and continuation of the current regimen. This patient exhibits a classic physiologic laboratory alteration caused by oral contraceptives. The estrogen component in combined oral contraceptives stimulates the liver to increase the synthesis of thyroxine-binding globulin (TBG) and decreases its clearance. Thyroid hormones (T4 and T3) circulate in the blood predominantly bound to carrier proteins like TBG, with only a tiny fraction remaining 'free' and biologically active. When TBG levels rise, more T4 is temporarily bound, momentarily decreasing the free T4 level. The normal hypothalamic-pituitary-thyroid axis responds instantly by increasing TSH secretion slightly, which prompts the thyroid gland to release more T4 until the new, larger pool of TBG is saturated. Once a new equilibrium is reached, the free T4 and TSH levels return to normal, but the total T4 remains elevated due to the increased bound fraction. Because the active (free) hormone level is normal, the patient remains completely euthyroid and asymptomatic, requiring no further diagnostic testing or treatment.

Step-by-Step Solution

Analyze the clinical presentation.

The patient is completely asymptomatic, has no signs of thyroid dysfunction on exam, and her acne is successfully improving on oral contraceptives.

To establish whether there is any clinical evidence of disease that warrants medical intervention.

Interpret the thyroid function panel.

The TSH and Free T4 are strictly within normal limits, while the Total T4 is markedly elevated.

To assess the biochemical functional state of the thyroid axis.

Correlate the abnormal lab finding with the patient's medication history.

The combined oral contraceptive pill contains estrogen, which increases hepatic production of thyroxine-binding globulin (TBG), directly explaining the isolated high Total T4.

To identify the etiology of the elevated Total T4 and confirm it is a benign physiologic response requiring no change in management.

Key Concept

Estrogen increases hepatic production of thyroxine-binding globulin (TBG). This raises the total circulating T4 levels but does not change the active free T4 or TSH levels in patients with a normal thyroid axis, requiring no treatment.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic